Patents by Inventor Christopher S. Poss

Christopher S. Poss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Piperazine derivatives
    Patent number: 7098212
    Abstract: The present invention relates to compounds of the formula I and the pharmaceutically acceptable forms thereof; wherein X, Y, a, b, c, d, R1, R2, R3, R4 and R5 are as defined herein. Moreover, the present invention is also directed at pharmaceutical compositions comprising a compound of the formula I and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed at methods of using the herein described compounds and compositions for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal.
    Type: Grant
    Filed: October 18, 2002
    Date of Patent: August 29, 2006
    Inventors: Laura C. Blumberg, Matthew F. Brown, Matthew M. Hayward, Gregory D. Lundquist, Christopher S. Poss, Andrei Shavnya
  • Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
    Publication number: 20040097554
    Abstract: The present invention relates to compounds of the formula (I) 1
    Type: Application
    Filed: October 16, 2003
    Publication date: May 20, 2004
    Applicant: Pfizer Inc
    Inventors: Matthew F. Brown, Anderson S. Gaweco, Ronald P. Gladue, John C. Kath, Christopher S. Poss
  • Methods of using piperazine derivatives
    Publication number: 20040092529
    Abstract: The present invention relates to compounds of the formula I 1
    Type: Application
    Filed: October 16, 2003
    Publication date: May 13, 2004
    Applicant: Pfizer Inc
    Inventors: Laura C. Blumberg, Matthew F. Brown, Anderson S. Gaweco, Ronald P. Gladue, Matthew M. Hayward, Gregory D. Lundquist, Christopher S. Poss, Andrei Shavnya
  • Methods of using CCR1 antagonists as immunomodulatory agents
    Publication number: 20040087571
    Abstract: The present invention relates to methods of using CCR1 antagonists as immunomodulatory agents.
    Type: Application
    Filed: October 16, 2003
    Publication date: May 6, 2004
    Applicant: Pfizer Inc
    Inventors: Matthew F. Brown, Anderson S. Gaweco, Ronald P. Gladue, John C. Kath, Christopher S. Poss
  • Crystal forms of quinoxaline-2-carboxylic acid [4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl]-amide
    Publication number: 20040072834
    Abstract: This invention relates to crystal forms of quinoxaline-2-carboxylic acid [4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl]-amide, useful in treating or preventing a disorder or condition by antagonizing the CCR1 receptor, and to their methods of preparation and use.
    Type: Application
    Filed: August 8, 2003
    Publication date: April 15, 2004
    Applicant: Pfizer Inc.
    Inventors: John C. Kath, Zheng J. Li, Zhengong B. Li, Eric McElroy, Clifford N. Meltz, Christopher S. Poss
  • Novel piperidine derivatives
    Publication number: 20040063759
    Abstract: A compound of the formula 1
    Type: Application
    Filed: July 8, 2003
    Publication date: April 1, 2004
    Applicant: Pfizer Inc.
    Inventors: Laura C. Blumberg, Matthew F. Brown, Matthew M. Hayward, Christopher S. Poss
  • Novel piperidine derivatives
    Publication number: 20040063688
    Abstract: A compound of the formula 1
    Type: Application
    Filed: July 8, 2003
    Publication date: April 1, 2004
    Applicant: Pfizer Inc.
    Inventors: Laura C. Blumberg, Matthew F. Brown, Matthew M. Hayward, Christopher S. Poss
  • Novel piperazine derivatives
    Publication number: 20040058932
    Abstract: A compound of the formula 1
    Type: Application
    Filed: September 10, 2003
    Publication date: March 25, 2004
    Applicant: Pfizer Inc.
    Inventors: Laura C. Blumberg, Matthew F. Brown, Ronald P. Gladue, Molly A. McGlynn, Christopher S. Poss
  • Novel piperazine derivatives
    Publication number: 20040034034
    Abstract: The present invention relates to compounds of the formula I 1
    Type: Application
    Filed: October 18, 2002
    Publication date: February 19, 2004
    Inventors: Laura C. Blumberg, Matthew F. Brown, Matthew M. Hayward, Gregory D. Lundquist, Christopher S. Poss, Andrei Shavnya
  • Quinoxalinyl carboxylic acid derivatives
    Patent number: 6689886
    Abstract: A compound of the formula XXXI or the pharmaceutically acceptable salt thereof; wherein R1, R2, and R3 are as defined herein and the compound is useful in the preparation or use of compounds that treat inflammation and other immune disorders.
    Type: Grant
    Filed: February 6, 2003
    Date of Patent: February 10, 2004
    Assignee: Pfizer Inc.
    Inventors: Matthew F. Brown, Christopher S. Poss
  • Piperazine derivatives
    Patent number: 6649611
    Abstract: A compound of the formula or the pharmaceutically acceptable salt thereof; wherein a, b, c, d, e, j, R1, R2, R3, and R4 are as defined herein and are useful to treat inflammation and other immune disorders.
    Type: Grant
    Filed: March 29, 2001
    Date of Patent: November 18, 2003
    Assignee: Pfizer, Inc.
    Inventors: Laura C. Blumberg, Matthew F. Brown, Ronald P. Gladue, Molly A. McGlynn, Christopher S. Poss
  • Novel heterocyclic amide derivatives
    Publication number: 20030204086
    Abstract: A compound of the formula XXXI 1
    Type: Application
    Filed: February 6, 2003
    Publication date: October 30, 2003
    Inventors: Matthew F. Brown, Christopher S. Poss
  • Quinoxalinyl amide derivatives
    Patent number: 6548671
    Abstract: A compound of the formula or the pharmaceutically acceptable salt thereof; wherein R1, R2, R3 and R4 are as defined above useful to treat inflammation and other immune disorders.
    Type: Grant
    Filed: January 31, 2001
    Date of Patent: April 15, 2003
    Assignee: Pfizer Inc
    Inventors: Matthew F. Brown, Christopher S. Poss
  • Treatment of T-cell mediated diseases
    Publication number: 20020168358
    Abstract: The present invention relates to the discovery that certain adverse inflammatory responses, allergic diseases, undesired immune responses including transplant rejection and autoimmune disease, and other disease states, can be treated or prevented by modulating the binding of the particular chemokines SLC (secondary lymphoid chemokine), and MIP-3b (macrophage inflammatory protein-3b), to immune system T cells and dendritic cells. The present invention is also related to methods for screening for therapeutic compounds useful in the treatment of SLC mediated and MIP-3b mediated disorders, and to the compounds detected by such screens. Appropriate assay methodology is also disclosed.
    Type: Application
    Filed: March 7, 2002
    Publication date: November 14, 2002
    Inventors: Ronald P. Gladue, William H. Martin, Christopher S. Poss
  • Novel heterocyclic amide derivatives
    Publication number: 20020132810
    Abstract: A compound of the formula 1
    Type: Application
    Filed: January 31, 2001
    Publication date: September 19, 2002
    Inventors: Matthew F. Brown, Christopher S. Poss
  • Bridged piperazine derivatives
    Publication number: 20020119961
    Abstract: A compound of the formula 1
    Type: Application
    Filed: October 5, 2001
    Publication date: August 29, 2002
    Applicant: Pfizer Inc.
    Inventors: Laura C. Blumberg, Matthew F. Brown, Ronald P. Gladue, Christopher S. Poss
  • Novel piperazine derivatives
    Publication number: 20020107255
    Abstract: A compound of the formula 1
    Type: Application
    Filed: March 29, 2001
    Publication date: August 8, 2002
    Inventors: Laura C. Blumberg, Matthew F. Brown, Ronald P. Gladue, Molly A. McGlynn, Christopher S. Poss
  • Thiono-lactone inhibitors of protein trafficking and uses therefor
    Patent number: 5516921
    Abstract: Novel compounds related structurally to Brefeldin A useful as antiviral, antifungal, antiproliferative, immunosuppresive and detoxifying agents as well as pharmaceutical compositions and methods based thereon are disclosed.
    Type: Grant
    Filed: September 19, 1994
    Date of Patent: May 14, 1996
    Assignee: Ariad Pharmaceuticals, Inc.
    Inventors: Manfred Weigele, Mallory F. Loewe, Christopher S. Poss
  • Process for producing electroluminescent yellow zinc sulfide phosphors
    Patent number: 5009808
    Abstract: A phosphor composition consisting essentially of particles of zinc sulfide electroluminescent phosphor activated with from about 0.7% by weight of about 1.3% by weight of manganese, based upon the total weight of the phosphor composition, wherein the electroluminescent emission of the phosphor has an x color coordinate value of from about 0.522 to about 0.532 and a y color coordinate value of from about 0.460 to about 0.470 and an efficiency of greater than about 5.6 lumens per watt at 115V/400 Hz. A solid state process for producing the foregoing phosphor comprises a multiple firing in order to incorporate manganese, chloride and copper ions into the zinc sulfide lattice. Controlled levels of manganese yield highly efficient electroluminescent phosphors.
    Type: Grant
    Filed: January 11, 1990
    Date of Patent: April 23, 1991
    Assignee: GTE Products Corporation
    Inventors: Kenneth T. Reilly, Richard G. W. Gingerich, Christopher S. Poss